[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05764642":3,"trial-entities:NCT05764642":97,"trial-summary:NCT05764642":101},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":46,"secondary_outcomes":57,"sex":58,"minimum_age":59,"maximum_age":17,"healthy_volunteers":60,"eligibility_criteria":61,"std_ages":69,"locations":72,"central_contacts":90,"overall_officials":91,"references":95,"see_also_links":96},"NCT05764642","22-006499","A Study of Renal Microvessel Imaging for Chronic Kidney Disease","Renal Microvessel Imaging for Characterization of Chronic Kidney Disease","ENROLLING_BY_INVITATION","2028-04","2025-09","2025-09-05","2023-08-09","Mayo Clinic","OTHER",false,"The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.",null,[19,20],"Healthy","Chronic Kidney Diseases",[],"INTERVENTIONAL","DIAGNOSTIC",[25],"PHASE2",{"count":27,"type":28},186,"ESTIMATED",[30,39],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":37},"DRUG","Definity","Ultrasound contrast agent administered intravenously",[35,36],"Chronic Kidney Disease Group","Healthy Control Group",[38],"Perflutren Lipid Microsphere",{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DIAGNOSTIC_TEST","Super-resolution ultrasound imaging","Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.",[35,36],[45],"SRUI",[47,51,54],{"measure":48,"description":49,"timeFrame":50},"Renal cortex microvessel density","Super-Resolution Ultrasound Imaging (SRUI) parameters reported in percentage","Baseline",{"measure":52,"description":53,"timeFrame":50},"Renal cortex microvessel diameter","Super-Resolution Ultrasound Imaging (SRUI) parameters reported in millimeters (mm)",{"measure":55,"description":56,"timeFrame":50},"Renal blood flow velocity","Super-Resolution Ultrasound Imaging (SRUI) parameters reported in centimeters per second (cm\u002Fsec)",[],"ALL","18 Years",true,{"inclusion":62,"exclusion":63,"raw_text":68},[],[64,65,66,67],"Subjects lacking capacity to consent.","Vulnerable subjects such as prisoners; pregnant women; nursing mother.","Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents.","Patients with high-risk cardiac diseases.","Inclusion Criteria:\n\n\\- Healthy volunteers or Chronic Kidney Disease (CKD) patients with clinically indicated renal biopsy.\n\nExclusion Criteria:\n\n* Subjects lacking capacity to consent.\n* Vulnerable subjects such as prisoners; pregnant women; nursing mother.\n* Subjects with history of hypersensitivity allergic reactions to ultrasound contrast agents.\n* Patients with high-risk cardiac diseases.",[70,71],"ADULT","OLDER_ADULT",[73,82],{"facility":74,"city":75,"state":76,"zip":77,"country":78,"geoPoint":79},"Mayo Clinic Florida","Jacksonville","Florida","32224","United States",{"lat":80,"lon":81},30.33218,-81.65565,{"facility":83,"city":84,"state":85,"zip":86,"country":78,"geoPoint":87},"Mayo Clinic Minnesota","Rochester","Minnesota","55905",{"lat":88,"lon":89},44.02163,-92.4699,[],[92],{"name":93,"affiliation":13,"role":94},"Shigao Chen, PhD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":98,"biomarkers":100},[99,19],"Chronic Kidney Disease",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]